Q1 Earnings Forecast for MREO Issued By Leerink Partnrs

Mereo BioPharma Group plc (NASDAQ:MREO) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mereo BioPharma Group in a report released on Monday, November 18th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of $0.00 for the quarter. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2026 earnings at $0.00 EPS.

MREO has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of “Buy” and an average price target of $7.50.

Mereo BioPharma Group Price Performance

Shares of NASDAQ:MREO opened at $3.58 on Wednesday. Mereo BioPharma Group has a 52-week low of $3.17 and a 52-week high of $5.02. The stock’s 50-day simple moving average is $4.18 and its two-hundred day simple moving average is $3.95.

Insiders Place Their Bets

In other news, CEO Denise Scots-Knight sold 28,611 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $127,891.17. Following the transaction, the chief executive officer now owns 868,967 shares of the company’s stock, valued at approximately $3,884,282.49. The trade was a 3.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christine Ann Fox sold 9,128 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total value of $40,802.16. Following the transaction, the chief financial officer now directly owns 108,443 shares in the company, valued at approximately $484,740.21. This represents a 7.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 52,931 shares of company stock valued at $236,602 in the last quarter.

Hedge Funds Weigh In On Mereo BioPharma Group

Large investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its holdings in Mereo BioPharma Group by 70.9% during the 2nd quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock valued at $25,000 after acquiring an additional 2,887 shares during the period. GAMMA Investing LLC boosted its holdings in Mereo BioPharma Group by 58.1% during the 3rd quarter. GAMMA Investing LLC now owns 10,693 shares of the company’s stock valued at $44,000 after acquiring an additional 3,928 shares during the period. SG Americas Securities LLC purchased a new position in Mereo BioPharma Group during the 1st quarter valued at $54,000. BNP Paribas Financial Markets lifted its holdings in shares of Mereo BioPharma Group by 581,066.7% in the 1st quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock worth $58,000 after buying an additional 17,432 shares during the period. Finally, State Street Corp purchased a new stake in shares of Mereo BioPharma Group in the 3rd quarter worth $195,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.